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Abstract
In a case-control study among 2064 South African women to investigate the risk of clinically
invasive cancer of the cervix, we found a marked reduction in the risk of cervical cancer among
women who gave a history of ever having undergone even a single Pap smear, and a statistically
significant decline in the HPV positivity rate correlated with the lifetime number of Pap smears
received. HPV infections and their associated low-grade lesions commonly regress, indicating that
most often there is an effective host immune response against HPV infection. We hypothesized that
act of performing a Pap smear is associated with inflammatory responses at the site of trauma, the
cervix, and that this inflammatory signalling may be an immunological factor initiating these
productive anti-HPV responses. In the present study, a randomized controlled trial, we enrolled 80
healthy young women to investigate the impact of performing a Pap smear on cervical inflammation.
Forty one women, in the intervention group, received a Pap smear at enrollment and cervicovaginal
lavages (CVLs) were collected at baseline and 2 weeks later. Thirty nine women received no
intervention at enrollment (control group) but CVLs were collected at enrolment and 2 weeks
later. We assessed various markers of inflammation including IL-12 p70, TNF-α, IL-8, IL-6, IL-10,
and IL-1β in CVL specimens. While CVL levels of IL-8, IL-1β and IL-6 remained unchanged following
a Pap smear, markers of cell mediated immunity (IL-12 p70 and TNF-α) and T cell regulation (IL-
10) were significantly elevated.
Background
In South Africa and worldwide, cervical cancer is the sec-
ond most common cancer in women with an overall age
standardized incidence rate of 30 per 100,000 [1]. Cervi-
cal cancer is predominantly a sexually transmitted disease
associated with infection with certain types of the human
papillomavirus (HPV) [2]. Internationally it has been
shown that screening for precursors of cervical cancer,
most commonly by means of Papanicoloau (Pap) smears,
substantially reduces the incidence of invasive cancer [3-
6]. We have recently completed a case-control study
among 2064 South African women to investigate the risk
of clinically invasive cancer of the cervix in relation to hor-
monal contraceptives use [7]. We found both a marked
reduction in the risk of cervical cancer among women
who gave a history of ever having undergone even a single
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Pap smear, and a 50% reduction in HPV prevalence
among woman who had undergone two or more smears.
There was a statistically significant decline in the HPV pos-
itivity rates according to the lifetime number of Pap
smears women had received [8].
HPV infections and their associated low-grade lesions
commonly regress [9], indicating that there is most often
an effective host immune response against HPV infection.
Regression of anogenital warts is associated with infiltra-
tion of T cells [10] and it is generally thought that regres-
sion is largely driven by HPV-specific immunity. We
hypothesize here that the minor trauma and associated
inflammatory responses involved in taking a Pap smear
may be an important factor initiating these productive
responses. This hypothesis is supported by the clinical
observation that genital condylomas and warts, also
known to be caused by specific HPV types [11], usually
regress, often without recurrence, following cauterization.
Furthermore, the effectiveness of topically applied Imiq-
uimod, an immune response modifier, in the treatment of
patients with HPV-associated genital and peri-anal warts
is well documented and has largely been ascribed to initi-
ation of inflammatory cytokine response cascades [12].
The aim of this study was to investigate the impact of
minor trauma to the cervix caused by a Pap smear on local
mucosal inflammatory responses. Comparing cervicovag-
inal lavage (CVL) specimens from healthy young women
who had recently received a Pap smear with those that had
not, we assessed various markers of inflammation includ-
ing (i) interleukin (IL)-12 p70 and tumour necrosis factor
(TNF)-α (associated with Th1 protective responses); (ii)
IL-8 (associated with neutrophil recruitment); (iii) IL-6
(associated with B cell recruitment); IL-10 (associated
with T cell regulation) and IL-1β (associated with leuko-
cyte recruitment, activation of NFκB and upstream induc-
tion of other cytokines, prostanoids and nitric oxide
associated with inflammation) [13-15].
Methods
A randomised controlled trial was conducted in which
women between the ages of 18 and 29 years were
recruited from the University of Cape Town Student
Health Clinic, Cape Town, South Africa. Women were eli-
gible to participate if they had been resident in the study
area for at least 6 months and had no previous history of
malignancy at any site. Women were ineligible if they had
(i) a current sexually transmitted infection (reported or on
examination), (ii) undergone a Pap smear within the pre-
vious 6 months, or (iii) used a vaginal medication during
the week prior to Visit 1 (baseline). Eligible and consent-
ing women were randomly assigned to either the interven-
tion or the control group. Women in the intervention
group received a cervico-vaginal lavage (CVL) followed
immediately by a Pap smear (at baseline), while women
in the control group received CVL at baseline, but only
received a Pap smear upon exit from the study (at Visit 2,
after 2 weeks of follow-up from Visit 1). To normalize for
potential changes in cytokine and/or protein concentra-
tions during the menstrual cycle [16,17] women were
enrolled 2–3 days following the last day of menses (base-
line during which the intervention group received a Pap
smear and both groups received CVL). Both intervention
and control participants were asked to return to the clinic
14 days later for the follow up visit (during which both
groups received a second CVL). Following this second
CVL, the women in the control group received a Pap
smear.
Information on socio-demographic characteristics, repro-
ductive history and sexual activity were collected from
participants by a questionnaire administered by the nurse
interviewer. The Research Ethics Committee of the Faculty
of Health Sciences, University of Cape Town approved the
study and written informed consent was obtained from all
women before participation.
Pap smears
Pap smears were taken using the Aylesbury spatula by
placing it in the cervical os and rotating it through 360°.
This instrument was used for taking Pap smears as it is the
one employed in the public health sector clinics in South
Africa. A cytologist screened the slides. Women with
abnormal Pap smears were referred to appropriate services
for management.
Collection and processing of cervical specimens
After consent, a vaginal examination was performed on all
participants. In the intervention group at baseline, the
CVL was performed immediately prior to the Pap smear.
In the control group, only a CVL was performed at base-
line. The CVL was performed by inserting 6 ml sterile PBS
into the external cervical os and irrigating the endocervical
region for approximately 30 seconds using a sterile dis-
posable plastic Pasteur pipette. The CVL fluid pooled in
the posterior fornix of the vagina was then withdrawn
using the same pipette. Good recovery of 5.5 – 6.0 ml PBS
per patient was recorded. The fluid was then transferred
into a sterile transport tube and transported to the labora-
tory at 4°C within 2 hours of collection. CVLs were proc-
essed immediately in the laboratory by centrifugation at
1000 × g for 10 minutes at 4°C and the aliquoted super-
natants stored at -80°C until further processing.
Determination of CVL protein concentrations
Protein concentrations in paired patient CVLs (baseline
and follow-up) were evaluated using the commercial BCA
Protein Assay Kit (Pierce, Rockford, IL, USA) according
the manufacturer's instructions.Journal of Inflammation 2007, 4:8 http://www.journal-inflammation.com/content/4/1/8
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Determination of inflammatory cytokine profiles in CVLs
Cervical cytokine responses were evaluated directly ex vivo
by evaluating inflammatory cytokine production profiles
in the supernatant fraction of the CVL sample using the
commercial Becton Dickenson Human Inflammation
Cytometric Bead Array (CBA) system and FACS analysis,
according the manufacturer's instructions. This system
allowed for detection of IL-8, IL-1β, IL-6, IL-10, TNF-α
and IL-12p70 per single patient specimen. Inflammatory
cytokine concentrations in the supernatant fraction of the
CVL sample were analyzed according the manufacturer's
instructions (BD Biosciences, San Diego, CA, USA). Fifty
µl of CVL was used per participant and each participant
sample was analyzed once. The sensitivity of this system
was between 1.9 and 7.2 pg/mL for each of the six
cytokines. Samples with cytokine levels below the lower
limit of detection of the assay were reported as zero, and
those above the upper detection limit of 5000 pg/mL were
assigned a value of 5000 pg/mL.
Statistical analysis
Statistical analyses were performed using Statistica® and
GraphPad Prism®. Unless otherwise indicated, the Mann-
Whitney U Test was applied for independent sample com-
parisons, the Wilcoxon Ranks Test was applied for
matched-pair comparisons and Spearman Ranks for cor-
relations. For comparison of cervical protein concentra-
tions, the Student's t-test for independent and dependent
samples was applied as indicated. P-values ≤ 0.05 were
considered statistically significant.
Results
Description of participants and randomization
Of the 90 women recruited, 9 were not eligible to partici-
pate for the following reasons: reported recent/current
genital herpes (n = 4), pregnant in the past 6 months (n =
2), inter-uterine device in the past 6 months (n = 1) and
never had vaginal sexual intercourse (n = 2). The remain-
ing 80 eligible women all consented to participate. Partic-
ipants were randomly assigned to either the intervention
(n = 41) or the control group (n = 40). No participants
withdrew from the study, but one in the control group
was lost to follow-up (intervention group = 41; control =
39).
Table 1 summarizes the socio-demographic, reproductive
and sexual characteristics by randomization group; no sig-
nificant differences were observed between these groups
at baseline or at follow-up (in terms of any vaginal inter-
course, number of acts of vaginal intercourse, condom use
and use of any vaginal medications during the study fol-
low-up period, data not shown). No participants received
a Pap smear outside the study during the study period.
There were 4/39 women in the control group and 4/41
women in the intervention group (Pap smears) who had
abnormal Pap smears during the study period (p = 0.95;
Χ2 test). In the control group, 3/4 women with abnormal
Pap smears had LSIL while 1/4 had ASCUS. In the inter-
vention group, 2/4 women with abnormal Pap smears
had LSIL while 2/4 had ASCUS.
Quantification of total protein concentrations in CVLs
Total protein in CVLs was determined at baseline (+3 days
post-menses) and at follow-up (14 days later or +17 days
post-menses) (Figure 1A). No significant difference in
total protein concentrations in CVLs was observed within
or between randomization groups.
Effect of Pap smear on cervical concentrations of 
inflammatory cytokines
CVLs from each participant were investigated for the pres-
ence of cervical inflammatory cytokines (IL-8, IL-1β, IL-6,
TNF-α, IL-12 p70 and IL-10) at baseline and follow-up
(Figure 1; see also Additional file 1 and 2). We found that
levels of IL-1β (Figure 1B), IL-8 (Figure 1C), and IL-6 (Fig-
ure 1D) did not differ significantly between baseline and
follow-up in either the control group (left panels) or the
intervention group (right panels) indicating that a Pap
smear was not detectably associated with increases in
these proinflammatory cytokines. In contrast, women
who received a Pap smear (intervention group) showed
significantly increased levels of the Th1 associated
cytokines TNF-α (Figure 1F; p = 0.025) and IL-12 p70
(Figure 1G; p = 0.0016) and the regulatory cytokine IL-10
(Figure 1E; p = 0.0003). When these cytokine responses
were scored according to whether the women had a
detectable cytokine response or not, significantly more
women from the intervention group had increased levels
of IL-12 p70 (p = 0.0007; Χ2 test) and IL-10 (p = 0.0003;
Χ2 test) (Table 2).
Discussion
In this study, we investigated the impact of minor trauma
to the cervix caused by a Pap smear on local mucosal
inflammatory responses. Concentrations of the inflam-
matory cytokines IL-12 and TNF-α and the regulatory
cytokine IL-10 were significantly increased in the genital
secretions (cervicovaginal lavage) of women who received
Pap smears compared with women who received no inter-
vention. In addition, significantly more women from the
intervention group had increased levels of IL-12 p70 and
IL-10. This is the first study to our knowledge to investi-
gate the effect of a Pap smear on cervical inflammation. It
remains to be determined whether this mucosal inflam-
matory response is linked to a lower incidence of HPV
infection.
There have been studies demonstrating that repetitive sex-
ual intercourse was associated with long-term protection
from HPV infection and the proposed mechanism for thisJournal of Inflammation 2007, 4:8 http://www.journal-inflammation.com/content/4/1/8
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was inflammation associated with repeated insult [18].
Studies on the topical immune response modifier, Imiq-
uimod [12,19,20], used in the treatment genital and peri-
anal warts provide further evidence that mild inflamma-
tion may be protective against HPV infection. Imiquimod
has been shown to activate both innate and cell mediated
immunity with local induction of inflammatory cytokines
IFN-α, IFN-γ, and TNF-α, [21-23]. Imiquimod-mediated
wart reduction was also associated with significant
decreases in HPV DNA copy number/cell [12,23] and
these studies have confirmed that this is largely due to
local inflammatory mediators.
The levels of IL-12 p70, IL-10 and TNF-α measured in this
study were quite low raising some concern about the bio-
logical significance of the changes observed between
groups. Despite this, concentrations of cytokines meas-
ured in this study were comparable to levels published
elsewhere when CVL [24] and cervical mucous were
assessed [25] confirming that these cytokines are present
and active at low concentrations. Evidence from vaginal
microbicide studies have shown that even low concentra-
tions of IL-1β and IL-6 (as little as a 9 pg/ml induction of
IL-1β) correlate significantly with vaginal irritation and
inflammation following application of vaginal microbi-
cides implying associated biological activity [26]. Finally,
the levels of TNF-α following cryo- or loop surgical treat-
ment of the cervix were shown to increase to a maximum
of 60 pg/ml at 14 days and this was associated with peak
inflammation and significant macroscopic ulceration of
the cervix [27]. Based on these modest levels following
more severe inflammatory interventions (surgery) than
used in this study (Pap smear), we argue that the small
changes observed following a Pap smear are biologically
relevant.
Since little data is available on the impact of female sex
hormones on cervical inflammatory cytokine responses,
our study normalized for menstral cycle changes by
obtaining CVLs from women 3 days post menses and 10
days later. Interestingly, we did not observe any significant
changes in the inflammatory cytokines assessed in the
control arm of the study. Although there is sound evi-
dence that levels of cervicovaginal antibodies are linked to
phases of the menstral cycle and that sex hormones
impact on this, there is no similar consensus on these
effects on mucosal cytokine secretion [28]. There have
been reports that levels of IL-10 and IL-1β are elevated at
the time of ovulation whereas IL-6 cervical concentrations
do not correlate with the ovulatory cycle or female sex
hormone levels [25]. In contrast, White et al. [28] showed
that intraepithelial lymphocyte and CTL activity persisted
in the vagina and cervix throughout the menstrual cycle
but was absent in the uterus during the secretory phase of
the cycle. Since inflammatory cytokines are secreted by
both epithelial cells and intraepithelial lymphocytes, it is
Table 1: Socio-demographic, reproductive and sexual characteristics by randomization group at enrolment
Characteristic Intervention: received a Pap Smear 
(n = 41)
Control: did not receive a Pap Smear 
(n = 39)
P-value
Age [median years (IQR)] 21.5 (20.0–23.0) 21 (20.0–22.8) 0.4
Vaginal intercourse during follow-up [n (%)] 21 (51.2) 17 (43.6) 0.5
Number of acts of vaginal intercourse [median years (IQR)] 3 (1.5–4.5) 1 (1–2) 0.1
Abnormal Pap smear during study [n (%)] 4 (9.8) 4 (10.3) 0.9
Ever pregnant [n (%)] 3 (7.1) 8 (20.0) 0.1
Number of live births among ever pregnant [n (%)] 0 (0.0) 2 (25.0) 0.2
Ever Pap smear [n (%)] 13 (30.9) 8 (20.0) 0.3
Number of Pap smears [median (IQR)] 2 (1–2) 1 (1–1.8) 0.2
Currently using hormonal contraception [n (%)] 19 (45.2) 17 (42.5) 0.8
Currently using [n(%)]
Condom 28 (66.7) 32 (80.0) 0.2
Combined oral contraceptive pills 13 (30.9) 8 (20.0) 0.3
Injectable 6 (14.6) 9 (22.5) 0.3
Ever vaginal discharge of concern [n (%)] 14 (33.3) 19 (47.5) 0.2
Age first vaginal intercourse [median years (IQR)] 18 (17–19) 17 (17–18.8) 0.4
Lifetime no. of sexual partners [median (IQR)] 2 (1–4) 2 (2–3) 0.5
Ever condom use [n (%)] 39 (92.8) 38 (95.0) 0.7
Always condom use [n (%)] 17 (43.5) 18 (47.4) 0.7
Rarely condom use [n (%)] 5 (12.8) 5 (13.2) 0.9
Use tampons when menstruating [n (%)] 25 (59.9) 26 (65.0) 0.6Journal of Inflammation 2007, 4:8 http://www.journal-inflammation.com/content/4/1/8
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Inflammatory cytokine and protein concentrations in cervicovaginal lavages (CVL) from women having received a Pap smear  (intervention group; right panel) compared to women who had not (control group; left panel) Figure 1
Inflammatory cytokine and protein concentrations in cervicovaginal lavages (CVL) from women having 
received a Pap smear (intervention group; right panel) compared to women who had not (control group; left 
panel). Total protein (A), IL-1β (B), IL-8 (C), IL-6 (D), IL-10 (E), TNF-α (F) and IL-12 p70 (G) concentrations were measured 
in the CVL fluid from each woman using the BD CBA Inflammation panel and FACS analysis. Each (● ) represents an individual 
woman's protein or cytokine concentration. Solid lines indicate the median concentration for each group. P-values were calcu-
lated using Wilcoxon Ranks test for matched non-parametric data and p-values ≤ 0.05 were considered significant.
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possible that sex hormone regulation of epithelial cells
may impact epithelial cell cytokine production [29,30].
We found no evidence to support this.
In conclusion, this study provides the first evidence that a
Pap smear does significantly up-regulate levels of inflam-
matory cytokines IL-12, TNF-α and IL-10 at the cervix.
This is an important step towards understanding whether
these local Pap smear-associated inflammatory responses
are one of the factors initiating more long-term protection
from HPV infection and clearance.
Additional material
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